Rentosertib Trial Shows Promising Signs of Biological Age Reversal in Lung Disease Patients
A small clinical trial found that rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis (IPF), may slow biological aging. Patients appeared 3-4 years younger on blood protein tests, though researchers caution this is preliminary and does not prove longevity benefits.